Vaxart's Oral Norovirus Vaccine Shows Promise in Early Trials for Elderly Adults

Phase 1b trial data reveals strong immune responses, reduced viral shedding, and potential for broader applications in combating viral diseases.

Vaxart's experimental oral norovirus vaccine demonstrated robust antibody and T-cell responses in adults aged 55-80, comparable to younger populations previously studied.
The vaccine induced significant mucosal immunity, with antibody increases observed in saliva, nasal cavities, and the gastrointestinal tract, suggesting potential protection against respiratory viruses.
Participants in the Phase 1b trial experienced an 85% reduction in viral shedding, indicating potential to limit virus transmission even in breakthrough infections.
The vaccine was well-tolerated, with mild to moderate side effects such as headache and fatigue reported at rates similar to the placebo group.
Vaxart is advancing second-generation vaccine candidates with improved immunogenicity, with clinical trial data expected by mid-2025.